Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,856 active trials61 approved drugs307 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,398 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06315270 | To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer | not yet recruiting | — | 100 | The First Hospital of Jilin UniversityOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT03973671 | Prospective Sample Collection for Cancer of Bladder(ProCaB) | recruiting | — | 300 | Universitaire Ziekenhuizen KU LeuvenOTHER |
| 1 |
| Mar 28, 2024 |
| clinicaltrials |
| NCT06335693 | Adjuvant Hypofractionated Radiotherapy for Prostate Cancer | recruiting | N/A | 9 | Changhai HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06333821 | A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma | not yet recruiting | Phase 3 | 460 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Mar 27, 2024 | clinicaltrials |
| NCT06325423 | Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06329323 | SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours(SUMMER) | not yet recruiting | — | 24 | Imperial College LondonOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06330909 | Image-guided Focal Dose Escalation- Primary pc Treated With Primary External Beam Hypofract.Stereotactic rt(HypoF-SBRT) | recruiting | N/A | 374 | University Hospital FreiburgOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06320223 | PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer(PROMISE-PET) | recruiting | — | 10,000 | University Hospital, EssenOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06321679 | Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone(RESPECT) | recruiting | — | 40 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06318559 | Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention(RIDERS) | recruiting | N/A | 120 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05200988 | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC(Indi-Blade) | active not recruiting | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05116475 | Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases(ALADDIN) | recruiting | Phase 3 | 152 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05219734 | MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment(MARIA) | active not recruiting | — | 400 | Invitae CorporationINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06305832 | Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | recruiting | Phase 2 | 102 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06292897 | Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression(OBESITA'&PCa) | recruiting | — | 25 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06289283 | Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder(Cancer bladder) | active not recruiting | — | 38 | Theodor Bilharz Research InstituteOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04612907 | Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer(Hypo-M1) | recruiting | N/A | 420 | Umeå UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04642027 | PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy(PERYTON) | recruiting | Phase 3 | 538 | University Medical Center GroningenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06155396 | A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 2 | 116 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06206083 | Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis | recruiting | — | 64 | National Institute of CancerologíaOTHER_GOV | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06284031 | Cervical Cancer Brachytherapy With Interstitial Needles in 3 Fractions | recruiting | N/A | 56 | National University Hospital, SingaporeOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04340245 | Exploiting Risk-Based Risk Stratification in Early Prostate Cancer to Discriminate Progressors From Non-Progressors(RECONCILE) | active not recruiting | — | 60 | University College, LondonOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06270043 | Focal Therapy for Localized Prostate Cancer | recruiting | — | 500 | University of California, San DiegoOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06278506 | Resection or Ablation of Small Kidney Tumors(RESTART) | recruiting | N/A | 300 | Karolinska University HospitalOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04029714 | Prostate Cancer Active Surveillance Trigger Trial (PCASTT-UK): Comparing Current Practice for Men With Prostate Cancer on Active Surveillance (AS) to an AS Protocol With Standardised Triggers for Transitioning to Curative Treatment | active not recruiting | N/A | 195 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06272240 | Tumor Microenvironment in Ovarian Cancer(MICO) | recruiting | — | 50 | University of UdineOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT06273553 | A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 | not yet recruiting | Phase 1 / Phase 2 | 39 | RinuaGene Biotechnology Co., Ltd.INDUSTRY | 0 | Feb 22, 2024 | clinicaltrials |
| NCT06269536 | Stress-reducing Intervention in Urothelial Carcinoma | recruiting | N/A | 50 | Comenius UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06271551 | Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy(ESTRACISE) | not yet recruiting | Phase 2 | 310 | Central Finland Hospital DistrictOTHER | 0 | Feb 21, 2024 | clinicaltrials |
| NCT06041555 | MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)(ISRAR) | recruiting | — | 600 | Hospices Civils de LyonOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06223295 | Effectiveness of Focal Therapy in Men With Prostate Cancer(ENFORCE) | recruiting | N/A | 356 | Radboud University Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06259123 | Neoadjuvant PSMA-RLT in Oligometastatic PCa | recruiting | Phase 2 | 10 | Medical University of ViennaOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT04909294 | Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma(STEREO-RML) | active not recruiting | N/A | 68 | Centre Georges Francois LeclercOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06255964 | A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 236 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Feb 13, 2024 | clinicaltrials |
| NCT06254729 | Clinical Study on the Evaluation of the Efficacy of Cervical Cancer(EECC) | not yet recruiting | — | 4,000 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Feb 12, 2024 | clinicaltrials |
| NCT06230549 | Adaptive Radiotherapy in Patients With Gynecological Tumors(ProART) | recruiting | N/A | 30 | University Hospital, EssenOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06251388 | A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer | recruiting | Phase 2 | 50 | West China Second University HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05983276 | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | recruiting | Phase 2 | 40 | Loyola UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06249308 | Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC ) | recruiting | — | 168 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06249750 | Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer | recruiting | Phase 2 | 60 | Pengyuan LiuOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05753826 | Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 37 | Fujian Cancer HospitalOTHER_GOV | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06244251 | Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids | active not recruiting | N/A | 5,000 | West China Second University HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06236789 | Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer | recruiting | — | 60 | Yonsei UniversityOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05731622 | Effect of a SI-MMC on the IVR Rate After Ureteroscopy for UTUC(SINCERE) | recruiting | — | 100 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06202339 | Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva (DaRT). | not yet recruiting | N/A | 10 | Alpha Tau Medical LTD.INDUSTRY | 0 | Jan 31, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Apr 1, 2024source: clinicaltrials